Medium NAPLEX Diabetes Case Practice Questions

A Medium NAPLEX Diabetes Case involves the clinical assessment and therapeutic management of patients with Type 1 or Type 2 diabetes, requiring an understanding of glycemic targets, medication mechanisms, and comorbid conditions. Navigating these cases is a core component of NAPLEX Prep, as they test your ability to apply guidelines from the American Diabetes Association (ADA) to realistic patient scenarios. These questions often bridge the gap between simple drug identification and complex clinical decision-making, focusing on dose adjustments, contraindications, and the selection of therapy based on cardiovascular or renal risk factors.

Concept Explanation

Diabetes management for the NAPLEX centers on achieving individualized glycemic goals while minimizing long-term complications such as neuropathy, retinopathy, and nephropathy. Pharmacists must be proficient in interpreting hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) levels to determine if a patient's current regimen is effective. For most non-pregnant adults, the standard target is an HbA1c of $< 7.0\%$, though this may be adjusted based on age or life expectancy.

Therapeutic selection has evolved to prioritize drugs with proven benefits for specific comorbidities. For example, patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD) should ideally receive a Glucagon-like peptide-1 (GLP-1) receptor agonist or a Sodium-glucose cotransporter-2 (SGLT2) inhibitor. Understanding the NAPLEX Renal Therapeutics Practice Questions is particularly helpful here, as many diabetes medications require dose modifications when the estimated glomerular filtration rate (eGFR) falls below certain thresholds, such as $30 \text{ mL/min/1.73m}^2$.

Insulin management remains a high-yield topic. Students must master the calculation of Total Daily Dose (TDD), insulin-to-carbohydrate ratios (ICR), and correction factors (sensitivity factors) using the Rule of 500 and Rule of 1800 for rapid-acting insulins. Safety is paramount, meaning you must recognize the signs of hypoglycemia and the appropriate "Rule of 15" for treatment: 15 grams of fast-acting carbohydrates followed by a recheck in 15 minutes.

Solved Examples

1. Total Daily Dose Calculation: A 24-year-old male with Type 1 Diabetes (weight 80 kg) is being started on a basal-bolus insulin regimen using a weight-based calculation of $0.5 \text{ units/kg/day}$. Calculate his basal dose and his mealtime dose per meal (assuming three meals).
   1. Calculate TDD: $80 \text{ kg} \times 0.5 \text{ units/kg} = 40 \text{ units}$.
   2. Split TDD into 50% basal and 50% bolus: 20 units basal, 20 units bolus.
   3. Divide bolus by 3 meals: $20 / 3 \approx 6.6$. Rounding to the nearest unit, he receives 7 units per meal.
   4. Final Answer: 20 units basal (e.g., glargine) and 7 units rapid-acting insulin with each meal.
2. Insulin Sensitivity Factor (ISF): A patient uses 60 units of total daily insulin (all rapid-acting for bolus). Using the Rule of 1800, calculate how much 1 unit of insulin will drop their blood glucose.
   1. Formula: $1800 / \text{TDD}$.
   2. Calculation: $1800 / 60 = 30$.
   3. Final Answer: 1 unit of insulin will lower the blood glucose by $30 \text{ mg/dL}$.
3. Drug Selection with Comorbidities: A 62-year-old female with Type 2 Diabetes (HbA1c 8.4%) has a history of Heart Failure with Reduced Ejection Fraction (HFrEF). She is currently on Metformin. Which class is preferred for addition to her therapy?
   1. Identify the compelling indication: Heart Failure.
   2. Reference ADA guidelines: SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) have shown significant benefit in reducing HF hospitalizations.
   3. Final Answer: An SGLT2 inhibitor is the preferred next step.

Practice Questions

1. A 55-year-old male with Type 2 Diabetes and a history of a myocardial infarction 2 years ago has an HbA1c of 7.8%. He is currently taking Metformin 1000 mg BID. Which of the following agents would be most appropriate to add to provide both glycemic control and cardiovascular benefit?

2. A patient with Type 1 Diabetes is transitioning to a pump. Their current total daily dose of insulin is 48 units. If the pump is set to deliver 40% of the TDD as a basal rate, what is the hourly basal rate in units/hour?

3. A patient presents with a blood glucose of $52 \text{ mg/dL}$. They are conscious and able to swallow. According to the "Rule of 15," which of the following is an appropriate initial treatment?

4. Which of the following diabetes medications should be avoided in a patient with a personal or family history of Medullary Thyroid Carcinoma (MTC)?

5. A patient taking canagliflozin (Invokana) should be counseled on the increased risk of which specific infection?

6. Calculate the Insulin-to-Carbohydrate Ratio (ICR) for a patient whose TDD is 50 units using the Rule of 500.

7. A patient with T2DM and an eGFR of $25 \text{ mL/min/1.73m}^2$ is currently taking Metformin. What is the most appropriate recommendation regarding their Metformin therapy?

8. Which of the following insulin types is generally clear in appearance and can be mixed in the same syringe with NPH insulin?

9. A patient is experiencing "dawn phenomenon." This is characterized by which of the following glucose patterns?

10. Which GLP-1 receptor agonist is available in an oral formulation?

Answers & Explanations

1. Answer: A GLP-1 Receptor Agonist (e.g., Liraglutide) or SGLT2 Inhibitor (e.g., Empagliflozin). For patients with established ASCVD, these two classes are preferred. You can find more details on medication classes in our NAPLEX Diabetes Medication Practice Questions with Answers.
2. Answer: 0.8 units/hr. First, calculate the daily basal amount: $48 \text{ units} \times 0.40 = 19.2 \text{ units/day}$. Then, divide by 24 hours: $19.2 / 24 = 0.8 \text{ units/hr}$.
3. Answer: 15 grams of simple carbohydrates (e.g., 4 oz orange juice or 3-4 glucose tablets). The Rule of 15 dictates 15g of carbs followed by a recheck in 15 minutes.
4. Answer: GLP-1 Receptor Agonists (e.g., Semaglutide, Dulaglutide). These carry a boxed warning for thyroid C-cell tumors based on animal studies.
5. Answer: Genital mycotic infections (yeast infections) and Urinary Tract Infections (UTIs). SGLT2 inhibitors cause glucosuria, which provides a substrate for fungal and bacterial growth in the genitourinary tract.
6. Answer: 10. Using the Rule of 500: $500 / 50 = 10$. This means 1 unit of insulin covers 10 grams of carbohydrates.
7. Answer: Discontinue Metformin. Metformin is contraindicated when the eGFR is $< 30 \text{ mL/min/1.73m}^2$ due to the risk of lactic acidosis. Review renal dosing for more information.
8. Answer: Regular Insulin (or rapid-acting like Aspart/Lispro). When mixing, remember the "clear before cloudy" rule (Regular/Rapid before NPH) to avoid contaminating the short-acting vial with NPH.
9. Answer: Hyperglycemia in the early morning. This is caused by the natural circadian release of growth hormone and cortisol, which increases hepatic glucose production. It differs from the Somogyi effect, which is rebound hyperglycemia following nocturnal hypoglycemia.
10. Answer: Rybelsus (Oral Semaglutide). It must be taken 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water.

1. Which of the following represents the correct mechanism of action for Sitagliptin?

• ASGLT2 inhibitor
• BDPP-4 inhibitor
• CGLP-1 receptor agonist
• DSulfonylurea

Frequently Asked Questions

What is the Rule of 500 in diabetes management?

The Rule of 500 is used to estimate the insulin-to-carbohydrate ratio (ICR) for patients using rapid-acting insulin. By dividing 500 by the total daily dose (TDD) of insulin, clinicians can determine how many grams of carbohydrates are covered by one unit of insulin.

How does eGFR affect Metformin dosing?

Metformin is contraindicated if the eGFR is below $30 \text{ mL/min/1.73m}^2$. If the eGFR is between 30 and 45, initiating Metformin is not recommended, and for those already taking it, a dose reduction of 50% is often advised while monitoring renal function closely.

What are the primary symptoms of hypoglycemia?

Common symptoms include shakiness, sweating, tachycardia, confusion, and dizziness. These are caused by the activation of the sympathetic nervous system and neuroglycopenia, requiring immediate treatment with fast-acting glucose.

When should a GLP-1 agonist be prioritized over other agents?

GLP-1 receptor agonists are prioritized in patients with established atherosclerotic cardiovascular disease (ASCVD) or those at high risk for it. They are also highly effective for weight loss and are preferred when minimizing hypoglycemia is a clinical priority.

What is the difference between DKA and HHS?

Diabetic Ketoacidosis (DKA) usually occurs in Type 1 Diabetes and is characterized by ketones, acidosis, and moderate hyperglycemia. Hyperosmolar Hyperglycemic State (HHS) typically occurs in Type 2 Diabetes, involving extreme hyperglycemia ($> 600 \text{ mg/dL}$) and profound dehydration without significant ketosis.

Can SGLT2 inhibitors be used in Type 1 Diabetes?

SGLT2 inhibitors are currently not FDA-approved for Type 1 Diabetes in the United States. Using them off-label in Type 1 patients significantly increases the risk of euglycemic diabetic ketoacidosis, which is difficult to detect because blood glucose levels may remain near normal.